Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors
- Seasoned executive with three decades of experience in pharma and biotech
- Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck)
- Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical trials for the treatment of severe erectile dysfunction (ED) following prostate cancer surgery
Copenhagen, Denmark, 4 September 2025 – Blue Cell Therapeutics, a biotech developing “off-the-shelf” allogeneic stem cell therapies for diseases where angiogenesis and nerve regeneration are beneficial, today announces the appointment of Olav Hellebø as Chairman of its Board of Directors.
